Citations

Citations to this article as recorded by  

• The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
  Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yasuhiro Fujiwara, Erika Cecchin
  PLOS ONE.2021; 16(4): e0250597.     CrossRef
• Advances in research of tacrolimus for treatment of inflammatory bowel disease
  Jing-Jing Wang, Yi-Hong Fan
  World Chinese Journal of Digestology.2019; 27(13): 842.     CrossRef

Ulcerative colitis (UC) is 1 of the 2 major phenotypes of chronic inflammatory bowel disease (IBD), which afflicts millions of individuals throughout the world with debilitating symptoms that impair function and quality of life. Further, IBD often affects women during childbearing age. Indeed, UC activity frequently increases during pregnancy, and the medications used to induce remission may adversely affect the health of the mother and the unborn child. We report successful induction of a remission in a UC case who experienced a flare-up in the first trimester of pregnancy. Upon relapse, she was treated with steroids and adsorptive granulomonocytapheresis (GMA) with the Adacolumn plus tacrolimus. This combination therapy induced a stable remission that was maintained during her entire pregnancy. She gave birth to a healthy child at 36 weeks of pregnancy with no maternal or fetal complications. Our experience indicates that GMA, as a non-drug therapeutic intervention with a favorable safety profile, plus tacrolimus might be a relevant treatment option for patients with active IBD during pregnancy. A future study of a large cohort of pregnant patients should strengthen our findings.

Citations

Citations to this article as recorded by  

• Adsorptive cytapheresis in ulcerative colitis: A non‐pharmacological therapeutic approach revisited
  Filippo Vernia, Angelo Viscido, Giovanni Latella
  Journal of Clinical Apheresis.2023; 38(6): 746.     CrossRef
• Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease
  Farah Yasmin, Hala Najeeb, Unaiza Naeem, Abdul Moeed, Thoyaja Koritala, Salim Surani
  World Journal of Clinical Cases.2022; 10(21): 7195.     CrossRef
• Reproductive Health in IBD Patients
  Sanket Patel, Haleh Vaziri
  Current Treatment Options in Gastroenterology.2021; 19(2): 237.     CrossRef
• Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future
  Xiu-Li Chen, Jing-Wei Mao, Ying-De Wang
  World Journal of Gastrointestinal Pathophysiology.2020; 11(3): 43.     CrossRef
• Women’s Health and Ulcerative Colitis
  Kindra Clark-Snustad, Madalina Butnariu, Anita Afzali
  Gastroenterology Clinics of North America.2020; 49(4): 769.     CrossRef

Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients. These studies showed that tacrolimus has excellent short-term efficacy in corticosteroid-refractory patients, with the rates of clinical response ranging from 61% to 96%. However, the long-term prognosis of patients treated with tacrolimus is disappointing, and almost 50% of patients eventually underwent colectomy in long-term follow-up. Tacrolimus can achieve mucosal healing in 40-50% of patients, and this is associated with a favorable long-term prognosis. Anti-tumor necrosis factor (TNF)-α antibodies are another therapeutic option in corticosteroid-refractory patients. A prospective head-to-head comparative study of tacrolimus and infliximab is currently being performed to determine which treatment is more effective in corticosteroid-refractory patients. Several retrospective studies have demonstrated that switching between tacrolimus and anti-TNF-α antibody therapy was effective in patients who were refractory to one of the treatments. Most adverse events of tacrolimus are mild; however, opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during treatment. Several issues on tacrolimus treatment in UC patients remain unsolved (e.g., use of tacrolimus as remission maintenance therapy). Further controlled studies are needed to optimize the use of tacrolimus for the treatment of UC.

Citations

Citations to this article as recorded by  

• Revolutionizing IBD therapy: Insights into contemporary treatment strategies
  Pooja Kushwaha, Rahila Qureshi, Nooruddin Khan, Sangita Mukhopadhyay
  International Reviews of Immunology.2026; 45(1): 1.     CrossRef
• Lactiplantibacillus plantarum ZJ316 Alleviates Helicobacter pylori-Induced Intestinal Inflammation by Sustaining Intestinal Homeostasis
  Shiying Wu, Fangtong Wei, Yongqiang Chen, Ziqi Chen, Yuenuo Luo, Jiayi Fan, Yang Xu, Mingyang Hu, Ping Li, Qing Gu
  Probiotics and Antimicrobial Proteins.2025; 17(6): 5195.     CrossRef
• Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
  Lynna Chen, Ashish Srinivasan, Suet‐Wan Choy, Jeffrey Van, Habeeb Habeeb, Andrew Nguyen, Abhinav Vasudevan
  Alimentary Pharmacology & Therapeutics.2025; 62(4): 400.     CrossRef
• A Clinical Prediction Model for Early Colectomy in Patients With Severe Ulcerative Colitis Treated With Tacrolimus
  Hikaru Shimizu, Kazuki Kakimoto, Mai Utsumi, Suzune Sugishima, Hideaki Mitooka, Noboru Mizuta, Ryosuke Yamaguchi, Masatoshi Kaizuka, Koji Nishida, Keijiro Numa, Naohiko Kinoshita, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Takako Miyazaki, Shiro Nakamura,
  JGH Open.2025;[Epub]     CrossRef
• Current Approaches to Ulcerative Colitis Management: A Comprehensive Overview of Methodologies and Treatments
  Aman Rawat, Richa Srivastava
  Infectious Disorders - Drug Targets.2025;[Epub]     CrossRef
• Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study
  Naoki Oshima, Sakiko Hiraoka, Ryohei Hayashi, Sakuma Takahashi, Manabu Ishii, Shinichi Hashimoto, Kazuo Yashima, Shoko Igawa, Toshihiro Inokuchi, Yoshitaka Ueno, Tomoki Inaba, Hiroshi Matsumoto, Kousaku Kawashima, Taro Takami, Hajime Isomoto, Akiko Shiota
  Inflammatory Bowel Diseases.2024; 30(7): 1087.     CrossRef
• RETRACTED ARTICLE: Exploring the therapeutic potential of Anastatica hierochuntica essential oil in DSS-induced colitis
  Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Mohammed Alqudah, Muna Oqal, Rawan Abudalo, Shtaywy S. Abdalla
  Inflammopharmacology.2024; 32(3): 2035.     CrossRef
• Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
  Javier P Gisbert, María José García, María Chaparro
  Journal of Crohn's and Colitis.2023; 17(6): 972.     CrossRef
• Gastrointestinal tract and viral pathogens
  Gowthami Sai Kogilathota Jagirdhar, Yashwitha Sai Pulakurthi, Himaja Dutt Chigurupati, Salim Surani
  World Journal of Virology.2023; 12(3): 136.     CrossRef
• Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection
  Ting Xue, Xiaomei Kong, Liang Ma
  Journal of Fungi.2023; 9(8): 812.     CrossRef
• Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease
  Florian Uellendahl-Werth, Carlo Maj, Oleg Borisov, Simonas Juzenas, Eike Matthias Wacker, Isabella Friis Jørgensen, Tim Alexander Steiert, Saptarshi Bej, Peter Krawitz, Per Hoffmann, Christoph Schramm, Olaf Wolkenhauer, Karina Banasik, Søren Brunak, Stefa
  Communications Biology.2022;[Epub]     CrossRef
• Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA–PABA–MAC and 5-ASA–PABA–Diamine for the Treatment of Ulcerative Colitis
  Jiaxing Zhao, Bing Zhang, Qing Mao, Kunqi Ping, Peng Zhang, Fengwei Lin, Dan Liu, Yao Feng, Ming Sun, Yan Zhang, Qiu Hua Li, Tingjian Zhang, Yanhua Mou, Shaojie Wang
  Journal of Medicinal Chemistry.2022; 65(6): 4926.     CrossRef
• Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis
  Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Mirela Pana, Rehab Gasiea, Gordon William Moran
  Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
• Combination tacrolimus and ustekinumab therapy is effective in inducing clinical, biochemical and endoscopic remission in refractory moderate to severe ulcerative colitis
  Rachit Gupta, Julien D. Schulberg, Ola Niewiadomski, Emily K. Wright
  Autoimmunity Reviews.2022; 21(7): 103115.     CrossRef
• Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis
  Sujaata Dwadasi, Maryam Zafer, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D Cohen, Joel Pekow, David T Rubin, Atsushi Sakuraba, Dejan Micic
  Inflammatory Bowel Diseases.2021; 27(10): 1620.     CrossRef
• Treatment of acute severe ulcerative colitis
  Jun-Rong Li, Fang-Mei Ling, Yi-Dong Chen, Ming-Yang Xu, Liang-Ru Zhu
  World Chinese Journal of Digestology.2021; 29(2): 87.     CrossRef
• Role of Topical Tacrolimus in the Management of Proctitis, Perianal Manifestations in Crohn's Disease, and Chronic Pouchitis: A Systematic Review
  George Salem, Kai Ding, Atsushi Sakuraba, Russell Cohen
  Journal of Investigative Medicine.2021; 69(4): 796.     CrossRef
• The Optimal Dose of Tacrolimus in Combination Therapy with an Anti-TNFα Antibody in a Mouse Colitis Model
  Yuki Murakami, Mikihiro Fujiya, Hiroaki Konishi, Shotaro Isozaki, Yuya Sugiyama, Yu Kobayashi, Takahiro Sasaki, Takehito Kunogi, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura
  Biological and Pharmaceutical Bulletin.2021; 44(4): 564.     CrossRef
• Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis
  Roberto Manzini, Marlene Schwarzfischer, Kirstin Atrott, Andrea Laimbacher, Silvia Lang, Marcin Wawrzyniak, Andreas Rickenbacher, Matthias Turina, Petr Hruz, Donata Lissner, Britta Siegmund, Gerhard Rogler, Michael Scharl, Marianne R Spalinger
  Inflammatory Bowel Diseases.2021; 27(12): 1986.     CrossRef
• The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
  Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yasuhiro Fujiwara, Erika Cecchin
  PLOS ONE.2021; 16(4): e0250597.     CrossRef
• De Novo Inflammatory Bowel Disease Rarely Occurs During Posttransplant Immunosuppression
  Jiayun M Fang, Laura Lamps, Amoah Yeboah-Korang, Jerome Cheng, Maria Westerhoff
  American Journal of Clinical Pathology.2021; 156(6): 1113.     CrossRef
• Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis
  Sara Hone Lopez, Gursah Kats-Ugurlu, Remco J. Renken, Henk J. Buikema, Marco R. de Groot, Marijn C. Visschedijk, Gerard Dijkstra, Mathilde Jalving, Jacco J. de Haan
  Virchows Archiv.2021; 479(6): 1119.     CrossRef
• Protective effects of selenium in tacrolimus-induced lung toxicity: potential role of heme oxygenase 1
  Salwa Abdel-Tawab Ibrahim, Nashwa Fathy Eltahawy, Ahlam Mohamed Abdalla, Hanaa Mohamed Khalaf
  Canadian Journal of Physiology and Pharmacology.2021; 99(10): 1069.     CrossRef
• Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review
  Biyu Wu, Jinglu Tong, Zhihua Ran
  Inflammatory Bowel Diseases.2020; 26(1): 24.     CrossRef
• Simple water‐based tacrolimus enemas for refractory proctitis
  Sasha R. Fehily, Felicity C. Martin, Michael A. Kamm
  JGH Open.2020; 4(4): 561.     CrossRef
• Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody
  Miki Kojima, Satoru Oji, Satoru Tanaka, Shoko Izaki, Baku Hashimoto, Hikoaki Fukaura, Kyoichi Nomura
  Multiple Sclerosis and Related Disorders.2020; 39: 101907.     CrossRef
• Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis
  Keiichi Haga, Tomoyoshi Shibuya, Kei Nomura, Koki Okahara, Osamu Nomura, Dai Ishikawa, Naoto Sakamoto, Taro Osada, Akihito Nagahara
  Journal of Clinical Medicine.2020; 9(6): 1771.     CrossRef
• Inflammatory Bowel Disease – Non-biological treatment
  Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
  Pharmacological Research.2020; 160: 105075.     CrossRef
• Lactobacillus plantarum L15 Alleviates Colitis by Inhibiting LPS-Mediated NF-κB Activation and Ameliorates DSS-Induced Gut Microbiota Dysbiosis
  Peng Yu, Chuxin Ke, Jiaxin Guo, Xiuling Zhang, Bailiang Li
  Frontiers in Immunology.2020;[Epub]     CrossRef
• 3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease
  Iria Seoane-Viaño, Noemí Gómez-Lado, Héctor Lázare-Iglesias, Xurxo García-Otero, José Ramón Antúnez-López, Álvaro Ruibal, Juan Jesús Varela-Correa, Pablo Aguiar, Abdul W. Basit, Francisco J. Otero-Espinar, Miguel González-Barcia, Alvaro Goyanes, Asteria L
  Biomedicines.2020; 8(12): 563.     CrossRef
• A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis
  Kiyonori Kobayashi, Yasuo Suzuki, Kenji Watanabe, Kazunori Oda, Miyuki Mukae, Akihiro Yamada, Hirokazu Yamagami, Akira Nishimura, Hiroyuki Okamoto
  The Journal of Clinical Pharmacology.2019; 59(2): 271.     CrossRef
• Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease
  Britt Christensen, Peter R. Gibson, Dejan Micic, Ruben J. Colman, Sarah R. Goeppinger, Olufemi Kassim, Andres Yarur, Christopher R. Weber, Russell D. Cohen, David T. Rubin
  Clinical Gastroenterology and Hepatology.2019; 17(3): 486.     CrossRef
• The protective role of phloretin against dextran sulfate sodium-induced ulcerative colitis in mice
  Zecai Zhang, Shan Li, Hongyang Cao, Peng Shen, Jiuxi Liu, Yunhe Fu, Yongguo Cao, Naisheng Zhang
  Food & Function.2019; 10(1): 422.     CrossRef
• Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction
  Yu Nishida, Shuhei Hosomi, Hirokazu Yamagami, Naoko Sugita, Shigehiro Itani, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara, Emiko Mizoguchi
  PLOS ONE.2019; 14(3): e0213505.     CrossRef
• Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis
  Peter Hoffmann, Cyrill Wehling, Johannes Krisam, Jan Pfeiffenberger, Nina Belling, Annika Gauss
  World Journal of Gastroenterology.2019; 25(13): 1603.     CrossRef
• Advances in research of tacrolimus for treatment of inflammatory bowel disease
  Jing-Jing Wang, Yi-Hong Fan
  World Chinese Journal of Digestology.2019; 27(13): 842.     CrossRef
• Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling
  Huining Fan, Wei Chen, Jinshui Zhu, Jing Zhang, Shiqiao Peng
  International Immunopharmacology.2019; 76: 105909.     CrossRef
• A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease
  Vito Annese
  Saudi Journal of Medicine & Medical Sciences.2019; 7(2): 66.     CrossRef
• Pharmacotherapy of ulcerative colitis – current status and emerging trends
  Hilal Ahmad, Vijay L. Kumar
  Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(6): 581.     CrossRef
• Updated treatment strategies for intestinal Behçet’s disease
  Yong Eun Park, Jae Hee Cheon
  The Korean Journal of Internal Medicine.2018; 33(1): 1.     CrossRef
• Tacrolimus: An updated review on delivering strategies for multifarious diseases
  Divya Dheer, Jyoti, Prem N. Gupta, Ravi Shankar
  European Journal of Pharmaceutical Sciences.2018; 114: 217.     CrossRef
• Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis
  Yi-Juan Liu, Hua Fan, Wei-Wei Zhen, Xing Yu, Jin-Tong Chen, Cheng-Dang Wang
  Medicine.2018; 97(32): e11440.     CrossRef
• Long-lasting Immunosuppressive Effects of tacrolimus-loaded Micelle NK61060 in Preclinical Arthritis and Colitis Models
  Takamichi Sato, Junpei Konno, Akihiro Sekiguchi, Nao Yoneki, Kana Kawano, Tomohiro Hayashi, Yukina Ogawa, Aya Kikitsu, Takashi Aijima, Kazuhisa Hara, Shintaro Hara, Hitomi Hayashi, Kimiko Fuchigami, Naoko Igo, Yuki Takashima, Yuki Kobayashi, Masayuki Mori
  Therapeutic Delivery.2018; 9(10): 711.     CrossRef
• In Vivo Study of the Efficacy of the Essential Oil of Zanthoxylum bungeanum Pericarp in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
  Zecai Zhang, Peng Shen, Jiuxi Liu, Cong Gu, Xiaojie Lu, Yanxin Li, Yongguo Cao, Bo Liu, Yunhe Fu, Naisheng Zhang
  Journal of Agricultural and Food Chemistry.2017; 65(16): 3311.     CrossRef
• Significant contribution of TRPC6 channel-mediated Ca²⁺ influx to the pathogenesis of Crohn’s disease fibrotic stenosis
  Lin Hai Kurahara, Keizo Hiraishi, Miho Sumiyoshi, Mayumi Doi, Yaopeng Hu, Kunihiko Aoyagi, Yuwen Jian, Ryuji Inoue
  Journal of Smooth Muscle Research.2016; 52: 78.     CrossRef